Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL

被引：0

作者：

Fiegl, Michael ^{[1
]}

Falkner, Florian ^{[1
]}

Falkner, Andreas ^{[1
]}

Zojer, Niklas ^{[2
]}

Fridrik, Michael ^{[3
]}

Hopfinger, Georg ^{[4
]}

Stauder, Reinhard ^{[5
]}

Gunsilius, Ebehard ^{[5
]}

Kantner, Johanna ^{[5
]}

Erdel, Martin ^{[5
]}

Tinhofer, Inge ^{[6
]}

Gastl, Guenther ^{[5
]}

Greil, Richard ^{[6
]}

机构：

[1] Acad Natters Hosp Tyrol, Natters, Austria

[2] Wilhelminenspital Stadt Wien, Vienna, Austria

[3] Gen Hosp Linz, Linz, Austria

[4] Hanuschspital, Vienna, Austria

[5] Med Univ Hosp, Innsbruck, Austria

[6] Med Univ Hosp, Salzburg, Austria

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4714

引用

页码：252B / 252B

页数：1

共 50 条

[31] Vitiligo after alemtuzumab treatment Secondary autoimmunity is not all about B cells
Ruck, Tobias
Pfeuffer, Steffen
Schulte-Mecklenbeck, Andreas
Gross, Catharina C.
Lindner, Maren
Metze, Dieter
Ehrchen, Jan
Sondermann, Wiebke
Pul, Refik
Kleinschnitz, Christoph
Wiendl, Heinz
Meuth, Sven G.
Klotz, Luisa
NEUROLOGY, 2018, 91 (24) : E2233 - E2237
[32] Hematological recovery after administration of subcutaneous alemtuzumab (MabCampath®) in previously untreated versus refractory B-CLL.
Lundin, J
Kimby, E
Mellstedt, H
Dyer, MJS
Hillman, P
Kennedy, B
Osterborg, A
BLOOD, 2002, 100 (11) : 805A - 805A
[33] Sequential treatment of B-CLL in daily practice
Schmid, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 1 - 2
[34] B-CLL: STRUCTURE AND RESULTS OF TREATMENT IN KYRGYZSTAN
Tsopova, I. A.
Murzamatova, Sh. K.
Astapova, S. G.
LEUKEMIA RESEARCH, 2017, 61 : S52 - S52
[35] Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin, J
Kimby, E
Björkholm, M
Broliden, PA
Celsing, F
Hjalmar, V
Möllgård, L
Rebello, P
Hale, G
Waldmann, H
Mellstedt, H
Österborg, A
BLOOD, 2002, 100 (03) : 768 - 773
[36] Methyl jasmonate: A new treatment for B-CLL?
Berrebi, Alain
Bassous, Lucette
Borenshtain, Rinat
Flescher, Eliezer
BLOOD, 2006, 108 (11) : 334B - 334B
[37] B-CLL: STRUCTURE AND RESULTS OF TREATMENT IN KYRGYZSTAN
Tsopova, I.
Murzamatova, S.
Astapova, S.
LEUKEMIA RESEARCH, 2017, 61 : S38 - S38
[38] EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient
Janssens, Ann
Berth, Mario
De Paepe, Pascale
Verhasselt, Bruno
Van Roy, Nadine
Noens, Lucien
Philippe, Jan
Offner, Fritz
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (09) : 706 - 712
[39] Immune competence after alemtuzumab treatment of multiple sclerosis
McCarthy, Claire L.
Tuohy, Orla
Compston, D. Alastair S.
Kumararatne, Dinakantha S.
Coles, Alasdair J.
Jones, Joanne L.
NEUROLOGY, 2013, 81 (10) : 872 - 876
[40] Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis
Brink, Huguette S.
Moll, Wibe
Sandberg, Yorick
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (01) : 13 - 13

← 1 2 3 4 5 →